• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Xenetic Biosciences Inc.

    10/31/25 4:20:12 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XBIO alert in real time by email
    DEFA14A 1 xenetic_defa14a.htm DEFINITIVE ADDITIONAL MATERIALS

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a)
    of the Securities Exchange Act of 1934

     

    (Amendment No.__)

     

    Filed by the Registrant ý
    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    o   Preliminary Proxy Statement

     

    o   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    o   Definitive Proxy Statement

     

    x   Definitive Additional Materials

     

    ¨   Soliciting Material Pursuant to § 240.14a-12

     

    XENETIC BIOSCIENCES, INC.

    (Name of Registrant as Specified In Its Charter)

     

    N/A

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box)

    ý   No fee required.
    o   Fee paid previously with preliminary materials.
    o   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

      

     

     

     

     

     

     

     

     

       
     

     

    Your Vote Counts! You invested in XENETIC BIOSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on December 11, 2024. Get informed before you vote View the Proxy Statement, Form 10 - K and Form 10 - K/A online OR you can receive a free paper or email copy of the material(s) by requesting prior to November 27, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V58353 - P19001 XENETIC BIOSCIENCES, INC. 945 CONCORD STREET FRAMINGHAM, MA 01701 XENETIC BIOSCIENCES, INC. 2024 Annual Meeting Vote by December 10, 2024 11:59 PM ET Vote Virtually at the Meeting* December 11, 2024 10:00 AM EST Virtually at: www.virtualshareholdermeeting.com/XBIO2024

     
     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. For 1. Election of Directors Nominees: 1) Grigory Borisenko 04) Roger Kornberg 2) Firdaus Jal Dastoor 05) Moshe Mizrahy 3) Dmitry Genkin 06) Alexey Vinogradov For 2. To ratify the selection by the Audit Committee of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. For 3. Non - binding advisory vote to approve the Company’s named executive officer compensation. 1 Year 4. Non - binding advisory vote to approve the frequency of holding future votes regarding named executive officer compensation (“Say on Frequency”). In his discretion, the proxy is authorized to vote upon such other business as may properly come before the meeting or any postponement or adjournment thereof. Voting Items Board Recommends V58354 - P19001

     

    Get the next $XBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XBIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $XBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

    Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platformWatch the "What This Means" video here FRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means

    12/17/24 9:15:00 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

    Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extended its previously announced Research Funding Agreement (the "Agreement") with the University of Virginia ("UVA") to advance the development of its systemic DNase program through 2025. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps (NETs), which are webl

    12/16/24 9:00:00 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

    Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 5, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has entered into a Clinical Trial Services Agreement (the "Agreement") with the Israel-based biotechnology company PeriNess Ltd. ("PeriNess") to advance the Company's development program for its systemic DNase I candidate in combination with chemotherapy and

    12/5/24 8:45:00 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XBIO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Xenetic Biosciences Inc.

    DEFA14A - Xenetic Biosciences, Inc. (0001534525) (Filer)

    10/31/25 4:20:12 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Xenetic Biosciences Inc.

    DEF 14A - Xenetic Biosciences, Inc. (0001534525) (Filer)

    10/31/25 4:10:39 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenetic Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)

    10/14/25 8:48:56 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Kornberg Roger D.

    4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

    12/13/24 5:00:09 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Dastoor Firdaus J.

    4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

    12/13/24 5:00:06 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Borisenko Grigory G.

    4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

    12/13/24 5:00:08 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XBIO
    Financials

    Live finance-specific insights

    View All

    Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

    Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunityDNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indicationsXenetic plans to conduct a Phase 1 clinical study of lead asset in locally advanced or metastatic solid tumorsCompany to host update conference call and webcast today, April 27th at 8:30 AM ETFRAMINGHAM, MA / ACCESSWIRE / April 27, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatm

    4/27/22 6:30:00 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XBIO
    Leadership Updates

    Live Leadership Updates

    View All

    $XBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Xenetic Biosciences, Inc. Announces Executive Leadership Transition

    Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward

    5/22/24 5:00:00 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

    Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertiseFRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P. Bissonnette, Ph.D. to serve as an executive consultant for translational research and development and to support the advancement of the Company's DNase-based oncology platform. Xenetic's DNase-based oncology platform is designed to target neutrophil extrace

    5/4/23 8:35:00 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

    Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planningFRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform. Mr. Cullison brings over 20 years of experience in the pharmaceutical industry. He has amassed a broad range

    5/3/23 8:35:00 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Xenetic Biosciences Inc. (Amendment)

    SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)

    3/18/24 1:45:06 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Xenetic Biosciences Inc. (Amendment)

    SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)

    9/18/23 12:21:48 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Xenetic Biosciences Inc.

    SC 13D - Xenetic Biosciences, Inc. (0001534525) (Subject)

    6/15/23 5:20:05 PM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care